"We believe the momentum we built in 2022 positions us for further success with our clinical and operational agenda in 2023," said Lisa Ricciardi, President and CEO of Cognition Therapeutics. "In the fourth quarter of 2022, we saw improvement in all key aspects of our business. On the capital front, we raised $6 million in a follow-on public offering, established an ATM program and, in the first quarter of 2023, secured up to an additional $35 million equity financing commitment from Lincoln Park Capital. In the clinic, we expanded our mild-to-moderate Alzheimer’s disease 144-patient SHINE study to include sites in Europe and began dosing patients. During the same period, as part of our mission to educate stakeholders on our programs and promote disease awareness, we launched a podcast series that features conversations with CNS experts and thought leaders to discuss key developments in the neurodegenerative disease space."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CGTX:
- Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
- Cognition Therapeutics to present proteomic biomarker analyses from CT1812
- Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023
- UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
- Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results